oppn parties Covaxin To Be Produced By Other Vaccine Manufacturers

News Snippets

  • EMI's set to rise after the RBI hikes key policy rate
  • Calcutta HC says that the right to privacy does not end with the death of a person
  • Supreme Court says that a delayed order of preventive detention makes it invalid
  • Shashi Tharoor posts an erronous map of India in his manifesto, rectifies the error after criticism
  • Sonia Gandhi to take a call on who will be Rajasthan chief minister
  • Mallikarujun Kharge to be the new candidate to oppose Shashi Tharoor in the Congress presidential elections
  • RBI says that the September inflation rate may be higher than 7%
  • RBI hikes key rates by 50bps, downwardly revises FY23 growth rate to 7% from 7.2% earlier
  • Stocks recover well on Friday: Sensex gains 1016 points to0 57426 and Nifty 276 points to 17094
  • Mirabai Chanu wins gold easily at the National Games
  • In a first, the Supreme Court recognizes marital rape, although for the limited purpose of allowing married women the right of abortion up to 24 weeks if they conceived as a result of forced sex by their husbands
  • Air India cuts discounts on base fare to students and senior citizens from 50% to 25%
  • Mallikarjun Kharge and Digvijay Singh are being touted as frontrunners to take on Shashi Tharoor in the elections for the post of Congress president
  • Sonia Gandhi will decide who will be Rajasthan CM if she feels there is a need to change guard after the near-rebellion by MLAs in the state
  • Ashok Gehlot bowed out of the race for being Congress president after meeting Sonia Gandhi
RBI hikes key rates by 50bps, stocks jump and recover 50% of the losses incurred in the last few session
oppn parties
Covaxin To Be Produced By Other Vaccine Manufacturers

By Linus Garg
First publised on 2021-05-14 01:29:06

About the Author

Sunil Garodia Linus tackles things head-on. He takes sides in his analysis and it fits excellently with our editorial policy. No 'maybe's' and 'allegedly' for him, only things in black and white.

Nearly a month after Prime Minister Modi first talked about using the entire vaccine manufacturing capacity in the country to produce the Covid vaccines and former prime minister and Congress leader Dr Manmohan Singh urged the government to invoke compulsory licensing provisions to allow all capable manufacturers to produce the vaccines, the government has invited all vaccine manufacturers in India to produce the indigenously developed (by ICMR and Bharat Biotech) Covaxin that is currently being made only by Bharat Biotech. NITI Aayog member Dr V K Paul said that Bharat Biotech has agreed to this arrangement.

This is a good move as it will help the government procure more doses from additional and captive sources at an attractive price. But it is regrettable that it took the government one month to take this decision. Under normal circumstances, such delays are part and parcel of both governance and corporate negotiations. But when there is a pandemic situation, the Disaster Management Act is in force and vaccines are in short supply threatening to derail the vaccine drive, one thinks decisions need to be taken on war footing. Such delays cannot be condoned in these troubled times.

But there is a stumbling block in the process as not all vaccine manufacturers in India have a BSL3 (Biosafety Level 3) lab which is necessary to inactivate a live virus in order to produce the Covid vaccines. The government must help those vaccine manufacturers who do not have this facility to get the lab up and running as fast as possible. It must provide them with funds and if import of equipment is required, it must allow and facilitate that. It must also assist them in getting the imported raw materials and provide them advance payments to fund their working capital requirements. Hopefully, once these manufacturers start production in full, there will be no vaccine shortage in India.